Edoxaban - Daiichi Sankyo Company

Drug Profile

Edoxaban - Daiichi Sankyo Company

Alternative Names: DU-176; DU-176b; Edoxaban tosilate hydrate; Edoxaban tosylate; LIXIANA; Lixiana; Lixiana OD; Roteas; SAVAYSA

Latest Information Update: 19 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation; Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
  • No development reported Venous thrombosis

Most Recent Events

  • 25 Aug 2018 Updated efficacy data from the phase III ENGAGE AF TIMI 48 trial in Atrial fibrillation (Stroke and Embolism) presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2018)
  • 06 Aug 2018 New efficacy data from the phase IIIb Hokusai-VTE CANCER trial in Venous thromboembolism released by Daiichi Sankyo
  • 28 Jun 2018 Edoxaban licensed to Menarini Asia-Pacific in Philippines, Malaysia and Singapore
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top